They are structurally unrelated peptides studied through different mechanisms
AOD-9604 operates through the beta-3 adrenergic pathway independent of the IGF-1 axis and GHRH pathway, making it a clean independent variable alongside IGF-1 LR3 or GHRH analogues like CJC-1295 and tesamorelin in multi-compound research designs
After 4 weeks at therapeutic doses, most users report 50-70% reduction in pain, significantly improved function, and ability to resume modified training or activities
HPLC purity assay Mass-spec identity Measured content 10.45 mg Test date 13/04/2026 Current batch NVBP10-01042026 Method HPLC LC-MS Certificate of Analysis available Download or independently verify the full third-party report for this peptide
Good fit reasons often include persistent low energy or fatigue, brain fog and a want for sharper mental clarity, slower recovery after exertion, and a broader interest in supporting healthy aging
Pharmacokinetic studies in animal models have further elucidated its properties